Ipsen Manufacturing
Ipsen is a biotechnological group aiming to become a leader in specialty healthcare solutions for debilitating diseases. Its strategy is supported by three franchises, neurology, endocrinology and urology-oncology.
Ipsen has a growing portfolio in prostate cancer, bladder cancer or neuro-endocrine tumours and a presence in primary care.
The group has more than 4,500 employees spread across R&D and manufacturing sites located in China, France, Ireland, the UK and the US.
Financial Data
-
31st Dec 16 Source: CRO
- €103 million turnover
-
€85.7 million
profit - 111 employees
-
31st Dec 15 Source: CRO
- €89.4 million turnover
-
€74.3 million
profit - 99 employees
- 4 more years available »
Ranking
By Turnover
(€103 million)- 458th in Top Companies
- 51st in Health
- 47th in Pharma
- 69th in Manufacturing
By Employees
(111)- 688th in Top Companies
- 81st in Health
- 62nd in Pharma
- 106th in Manufacturing
- 111
- €103 million
Employees
- James Byrne General Manager
Latest News
- Jan 18 High Court rules in case of four Caribbean-registered firms
- Jan 18 Travelodge boosts pretax profits at Tifco to €11.8m in 2017
- Jan 18 European shares rise to highest in six weeks
- Jan 18 Holiday home management company sues operators at estate over maintenance
- Jan 18 Spain plans 3% ‘Google’ tax on large tech companies